Abstract-The antiarrhythmic effect of aprindine was compared with those of lidocaine and propranolol on several ventricular arrhythmias-epinephrine arrhythmias in cats, ouabain arrhythmias in cats and guinea pigs, ischemic ventricular arrhythmias in coronary-ligated Beagle dogs. Antiarrhythmic effects of aprindine and lidocaine were observed both in ouabain and ischemic arrhythmias, but not in epinephrine arrhythmias. While propranolol had a strong antiarrhythmic effect against epinephrine and ouabain arrhythmias, it did not increase sinus beats in ischemic arrhythmias.
Pharmacological study of aprindine (A. Christiaens, AC1802; N- (3-diethylamino) propyl)-N-phenyl-2-indanamine)
by Georges et al. (1) showed that the antiarrhythmic effects of aprindine were present both in ouabain arrhythmias and ischemic ventricular arrhythmias in dogs. These workers also reported the superior local anesthetic activity of aprindine to lidocaine, tetracaine, and procaine.
Fasola (2) and Kesteloot et al. (3) clinically confirmed the antiarrhythmic effect of aprindine, i.e., prevention of premature ventricular beats. From electrocardiograms of arrhythmic patients, Gleichmann et al. (4) observed that aprindine as well as ajmaline retarded conduction in the His bundle. Orally administered aprindine is said to be more favorable than intravenously administered lidocaine for ventricular arrhythmias in patients with acute myocardial infarction (5) .
We compared antiarrhythmic effects of aprindine on several ventricular arrhythmias in cats, guinea pigs and dogs with those of lidocaine, propranolol, ajmaline, quinidine, and procaine amide.
MATERIALS AND METHODS

Epinephrine arrhythmias:
Male cats weighing 2.2-5.2 kg were anesthetized with pentobarbital-Na (25 mg/kg, i.v.) and urethane (0.6 g/kg, s.c. No antiarrhythmic effects were noticed for aprindine, lidocaine, and ajmaline even at their maximal dose, although marked antiarrhythmic effects were observed using pre treatment of propranolol (0.5 mg/kg, i.v.) and quinidine (10 mg/kg, i.v.) and some effects using procaine amide (Table 1 , Fig. 2 ).
Effects on ouabain arrhytlnnias in cats
By cumulative intravenous administration of ouabain at doses of 60-75 '"g/kg, sinus rhythm was converted to ventricular rhythm via ventricular extrasystole in 6 control cats (Fig. 3) . The ventricular rhythm continued for more than 3 hr in 3 cats and for about 1 hr in the other 3. In the latter group, cardiac arrest was observed after ventricular flutter or fibrillation. Spontaneous recovery from ventricular rhythm to sinus rhythm was not observed.
Intravenous infusion of antiarrhythinic compounds: Recovery from ventricular rhythm to sinus rhythm was observed with the intravenous infusion of aprindine (200 pg/kg/min, 5-7 mg/kg) in 3 out of 8 cats ( Table 2 ). The established sinus rhythm continued for more than 2 hr. Further infusion of aprindine was discontinued, because the characteristic pattern of ECG II by the cardiotoxic doses of aprindine-some notch on R spike, irregular height of R spike, widening of QRS complex, and depression of ST segment was observed.
Lidocaine infusion (400 Pg/kg/min, 15-20 mg/kg) converted ventricular rhythm to sinus rhythm in all experiments and the established sinus rhythm was stable for more than 2 hr. 
Effects on ischemic arrhythmias in dogs
Twenty-four hr after a ligation of the anterior descending branch of the left coronary artery, marked ventricular rhythm interspersed by a few sinus beats was observed in dogs.
As shown by Fig. 4 , SR and NSR were stable for longer periods. 
DISCUSSION
Antiarrhythmic effects of aprindine, lidocaine, propranolol, and ajmaline on epine phrine, ouabain, and ischemic arrhythmias are summarized in Table 8 . 1) Although anti arrhythmic effects of propranolol were observed both in epinephrine and ouabain arrhy thmias, an increase of sinus beats did not appear in ischemic arrhythmias with propranolol.
2) Aprindine and lidocaine, on the other hand, did not show any antiarrhythmic effects on epinephrine arrhythmias, but significantly increased sinus beats in ischemic arrhythmias.
These two points seem to be the most interesting in the present experiments.
In recording electrocardiograms of ischemic epi and endocardium, Wendt (8) observed that isoproterenol augmented the rise of ST segment but propranolol decreased it. Verrir et al. (9) showed that the fibrillation threshold was lowered at the time of coronary ligation and release. Since propranolol antagonized the lowering of the fibrillation threshold at the time of coronary ligation without any antagonism at coronary release, it was presumed that a release of norepinephrine was associated with the lowering of the fibrillation threshold at the time of coronary ligation.
Reimer and Jennings (10) histologically examined the effect of propranolol on the posterior papillary muscle with coronary ligation. Propranolol had some preventive effect but had no therapeutic effect on the necrotic tissue.
Since the norepinephrine content of the myocardium of dog (11, 12, 13) and pig (14) was markedly decreased by coronary ligation, it was presumed that norepinephrine was released upon coronary ligation and the released norepinephrine was related to eliciting ventricular arrhy thmias. Thus, propranolol would have an effect on the ventricular arrhythmias in the acute myocardial infarction. In this experiment, however, antiarrhythmic effects were The antiarrhythmic effects of aprindine in the various arrhythmias were similar to those of lidocaine as shown in Table 8 . Vaughan Williams (16) observed that lidocaine depressed the maximal rate of depolarization in the myocardium, but other workers (17) reported that lidocaine had no effect on the action potentials in the Purkinje fiber, atrium, and ventricular muscle. Williams (19) . Verdonck et al. (20) reported that these effects of aprindine were most clearly observed in the Purkinje fiber but not as markedly in the contractile myocardium.
They also observed that the effect of aprindine was long-lasting and tissue concentration of aprindine became about 10 times higher than the concentration in the bathing medium.
Therefore the antiarrhythmic mechanism of aprindine is presumed to be based on its in hibition of the maximal rate of depolarization (inhibition of sodium influx) and pacemaker activity. These effects of aprindine presumably suppress the ectopic focus in the ischemic myocardium. The shortening of the refractory period by aprindine (20) may explain to some extent the arrhythmogenic effect.
In ouabain arrhythmias, oral administration of aprindine produced an antiarrhythmic effect in cats but not in guinea pigs, while the effects of lidocaine were vice versa. Thus, it is difficult to conclude that oral administration of aprindine is superior to that of lidocaine for antiarrhythmic activity. Intravenously administered lidocaine showed a lasting anti arrhythmic effect on ouabain arrhythmias in cats but its effect on ischemic arrhythmias in dogs did not last so long as that of aprindine. For both ouabain and ischemic arrhythmias, the antiarrhythmic dose of aprindine was about one-half that of lidocaine, but acute toxicity of aprindine in mice and rats was about twice as strong as that of lidocaine (private com munication from Dr. Y. Hayashi).
In conclusion, aprindine as a potent antiarrhythmic agent seems to be equivalent to lidocaine. The marked antiarrhythmic effect of aprindine on ischemic arrhythmias, how ever, is deemed worthy of further investigation.
